China Regenerative Medicine International (HKSE:08158) GF Value : HK$0.58 (As of Dec. 14, 2024)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International GF Value?

As of today (2024-12-14), China Regenerative Medicine International's share price is HK$0.46. China Regenerative Medicine International's GF Value is HK$0.58. Therefore, China Regenerative Medicine International's Price-to-GF-Value for today is 0.79. Based on the relationship between the current stock price and the GF Value, GuruFocus believes China Regenerative Medicine International is Modestly Undervalued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

China Regenerative Medicine International (HKSE:08158) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

China Regenerative Medicine International's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.46	/	0.58
	=	0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Regenerative Medicine International GF Value Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310–18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Wang Chuang	2101 Beneficial owner
Wong Kwok Keung	2501 Other
Arab Osman Mohammed	2501 Other
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
China Orient Alternative Investment Fund	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines